Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Acquired by Signature Estate & Investment Advisors LLC

Signature Estate & Investment Advisors LLC grew its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 9.7% in the 4th quarter, HoldingsChannel reports. The firm owned 327 shares of the biopharmaceutical company’s stock after acquiring an additional 29 shares during the quarter. Signature Estate & Investment Advisors LLC’s holdings in Regeneron Pharmaceuticals were worth $233,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of REGN. State Street Corp grew its position in Regeneron Pharmaceuticals by 1.3% during the 3rd quarter. State Street Corp now owns 4,902,404 shares of the biopharmaceutical company’s stock worth $5,153,603,000 after purchasing an additional 61,277 shares in the last quarter. Amundi boosted its position in shares of Regeneron Pharmaceuticals by 45.8% in the fourth quarter. Amundi now owns 1,551,735 shares of the biopharmaceutical company’s stock worth $1,138,074,000 after buying an additional 487,489 shares during the period. Charles Schwab Investment Management Inc. grew its holdings in shares of Regeneron Pharmaceuticals by 3.3% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 695,799 shares of the biopharmaceutical company’s stock valued at $495,639,000 after buying an additional 22,538 shares in the last quarter. TD Asset Management Inc. raised its position in Regeneron Pharmaceuticals by 8.9% during the fourth quarter. TD Asset Management Inc. now owns 359,389 shares of the biopharmaceutical company’s stock valued at $256,004,000 after buying an additional 29,322 shares during the period. Finally, Sumitomo Mitsui Trust Group Inc. lifted its stake in Regeneron Pharmaceuticals by 0.4% in the 4th quarter. Sumitomo Mitsui Trust Group Inc. now owns 302,616 shares of the biopharmaceutical company’s stock worth $215,562,000 after acquiring an additional 1,108 shares in the last quarter. Institutional investors and hedge funds own 83.31% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on REGN. Bernstein Bank lowered their target price on Regeneron Pharmaceuticals from $1,070.00 to $1,000.00 in a research note on Tuesday, February 4th. Canaccord Genuity Group initiated coverage on shares of Regeneron Pharmaceuticals in a research report on Tuesday, December 17th. They set a “hold” rating and a $165.00 price objective on the stock. Sanford C. Bernstein cut their target price on shares of Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an “outperform” rating for the company in a research report on Tuesday, January 7th. Canaccord Genuity Group lowered shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, December 17th. Finally, Leerink Partnrs raised shares of Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, February 5th. One investment analyst has rated the stock with a sell rating, six have issued a hold rating, seventeen have given a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $973.13.

Regeneron Pharmaceuticals Price Performance

Shares of Regeneron Pharmaceuticals stock opened at $635.83 on Friday. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.73 and a quick ratio of 3.95. The company has a market cap of $69.51 billion, a PE ratio of 16.61, a price-to-earnings-growth ratio of 2.34 and a beta of 0.27. The firm has a fifty day moving average price of $684.76 and a two-hundred day moving average price of $803.87. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $629.02 and a fifty-two week high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share for the quarter, topping analysts’ consensus estimates of $11.21 by $0.86. The business had revenue of $3.79 billion for the quarter, compared to the consensus estimate of $3.76 billion. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The firm’s revenue for the quarter was up 10.3% compared to the same quarter last year. During the same period last year, the business earned $11.86 earnings per share. Analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Thursday, March 20th. Stockholders of record on Thursday, February 20th were given a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.55%. The ex-dividend date of this dividend was Thursday, February 20th. Regeneron Pharmaceuticals’s dividend payout ratio is presently 2.30%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.